Investigators Find Whistleblower Rick Bright Was Likely Retaliated Against, Lawyers Say

TOPLINE

The Office of Special Counsel believes White House whistleblower Rick Bright was likely retaliated against by the Trump administration, his lawyers said in a statement Friday, and the agency recommended that Bright be allowed to resume his previous job duties while his whistleblower complaint is investigated.

KEY FACTS

The OSC has found “reasonable grounds” to believe the Trump administration retaliated against Bright when he was removed as Director of the Biomedical Advanced Research and Development Authority, a research unit within the Department of Health and Human Services, last month.

The agency recommended that Bright be reinstated for 45 days while it investigates the claims laid out in a formal whistleblower complaint Bright filed earlier this week.

Bright said he was transferred to a lesser position because he opposed the Trump Administration’s push for unproven antimalarial drugs chloroquine and hydroxychloroquine.

Bright also alleged in the complaint HHS prioritized contracts based on “political favoritism” and “cronyism.”

Trump has previously dismissed Bright’s claims and called him a “disgruntled employee.”

OSC recommendations are not binding and HHS could ignore it if they choose.

OSC declined to comment because the investigation is still ongoing.

Crucial quote

“Dr. Bright should not be denied the right to have his complaint investigated fully and fairly before he is formally transferred to NIH — a move that will harm not only him, but the country as well,” Bright’s lawyers said in the statement. “We hope the Secretary will grant the Special Counsel’s request and allow Dr. Bright, one of the nation’s leading vaccine scientists, to return to his position leading BARDA and serving his country.”

key background

In mid-March, President Donald Trump and the White House began promoting chloroquine and hydroxychloroquine as possible treatments for COVID-19 after it was covered widely on Fox News and received attention in right-wing circles. But since there wasn’t any clinic trial data proving their effectiveness, the White House’s rush to make the drug available raised concerns in the scientific community.

Full coverage and live updates on the Coronavirus

Speak Your Mind

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get in Touch

350FansLike
100FollowersFollow
281FollowersFollow
150FollowersFollow

Recommend for You

Oh hi there 👋
It’s nice to meet you.

Subscribe and receive our weekly newsletter packed with awesome articles that really matters to you!

We don’t spam! Read our privacy policy for more info.

You might also like

Tastemade Goes After Spanish-Language Audience With Launch Of Tastemade...

ArgenMex is one of the series featured in...

Markets open marginally higher, Nifty below 11,150

New Delhi: Markets opened marginally higher on on Monday tracking positive Asian shares. The BSE...

Trump Says He’ll Veto Defense Bill If Confederate-Named Military...

TOPLINE In a late night tweet Tuesday, President Trump promised to veto a defense...